AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

New Compound May Be Future Of Breast Cancer Treatment

 cancer  Comments Off on New Compound May Be Future Of Breast Cancer Treatment
Jul 142013
 
Image Credit: Photos.com

Rebekah Eliason for redOrbit.com – Your Universe Online

Scientists from Melbourne, Australia recently discovered compounds currently being researched to treat leukemia may also be effective in treating the most common form of breast cancer.

Researchers found a group of anti-cancer compounds known as BH3-mimetics are effective for treating estrogen receptor-positive (ER-positive) forms of breast cancers when used with tamoxifen, a drug currently used to treat breast cancer. Breast cancer is comprised of roughly 70 percent ER-positive types.

http://www.redorbit.com/news/health/1112893311/compound-bh3-mimetics-future-of-breast-cancer-treatment-070913/

 

Share

FDA Accepts Eliquis sNDA

 sNDA  Comments Off on FDA Accepts Eliquis sNDA
Jul 122013
 

APIXABAN

Bristol-Myers Squibb and Pfizer announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis, for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients who have undergone hip or knee replacement surgery.FULL STORY

http://www.dddmag.com/news/2013/07/fda-accepts-eliquis-snda?et_cid=3362797&et_rid=523035093&type=headline

 

Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and venous thromboembolic events. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011 and was approved for preventing venous thromboembolism after elective hip or knee replacement. The FDA approved apixaban in December 2012 with an indication of reducing the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb

Share

Enhancing Neurological Drug Delivery

 Uncategorized  Comments Off on Enhancing Neurological Drug Delivery
Jul 122013
 

 

The challenge of delivering drugs to neurological targets has been a major roadblock to many promising therapies for treating diseases and disorders of the brain. The blood brain barrier blocks the vast majority of all small-molecules and virtually all large molecules from reaching therapeutic targets within the brain.FULL STORY

http://www.dddmag.com/articles/2013/07/enhancing-neurological-drug-delivery?et_cid=3362797&et_rid=523035093&type=cta

 

Share

AstraZeneca Buys Omthera for $323M, Expands Fleet of Cholesterol Fighters

 Uncategorized  Comments Off on AstraZeneca Buys Omthera for $323M, Expands Fleet of Cholesterol Fighters
Jul 112013
 
AstraZeneca
  • AstraZeneca
  • Published May 28, 2013
  • FOXBusiness

AstraZeneca (AZN) inked a deal on Tuesday to buy Omthera Pharmaceuticals (OMTH) for $323 million, acquiring an assortment of new therapies aimed at tackling cholesterol.

http://www.foxbusiness.com/news/2013/05/28/astrazeneca-buys-omthera-pharmaceuticals-for-127share/

Read more:

http://www.foxbusiness.com/news/2013/05/28/astrazeneca-buys-omthera-pharmaceuticals-for-127share/#ixzz2Yhwl9KUq

Share

Comparative Study of Dossier Compilation & Submission Process of Drug Product in USA, Europe & India. by DeveshDRA

 regulatory  Comments Off on Comparative Study of Dossier Compilation & Submission Process of Drug Product in USA, Europe & India. by DeveshDRA
Jul 102013
 

Comparative Study of Dossier Compilation & Submission Process of Drug Product in USA, Europe & India.

wait for slideshare to load…………….

Share

Medicare Officials Want More Amyvid Trials

 Uncategorized  Comments Off on Medicare Officials Want More Amyvid Trials
Jul 092013
 

 

Amyvid

Medicare Officials Want More Amyvid Trials

Eli Lilly & Co. says it will push ahead with an imaging chemical designed to help screen for Alzheimer’s disease, despite a negative ruling by Medicare officials. The Centers for Medicare and Medicaid Services said last week it will not cover the chemical which highlights brain plaque in medical imaging scans.

FULL STORY

 

Eli Lilly & Co. says it will push ahead with a first-of-a-kind imaging chemical designed to help screen for Alzheimer’s disease, despite a negative ruling by Medicare officials.

The Centers for Medicare and Medicaid Services said last week it will not cover the chemical, called Amyvid, which highlights brain plaque in medical imaging scans. The government program provides health coverage to more than 47 million seniors, and is the largest payer for prescription drugs in the U.S.

http://www.dddmag.com/news/2013/07/medicare-officials-want-more-amyvid-trials?et_cid=3356136&et_rid=523035093&type=cta

Amyvid contains florbetapir F 18, a molecular imaging agent that binds to β-amyloid aggregates, and is intended for use with PET imaging of the brain. Chemically, florbetapir F 18 is described as (E)-4-(2-(6-(2-(2-(2[18F] fluoroethoxy)ethoxy)ethoxy)pyridine3-yl)vinyl)-N-methylbenzamine. The molecular weight is 359 and the structural formula is:

 

Amyvid (Florbetapir) Structural Formula Illustration

 

Amyvid is a sterile, non-pyrogenic radioactive diagnostic agent for intravenous injection. The clear, colorless solution is supplied ready to use and each milliliter contains 0.1 to 19 micrograms of florbetapir and 500 – 1900 MBq (13.5 – 51 mCi) florbetapir F 18 at EOS, with 4.5 mg sodium ascorbate USP, and 0.1 mL dehydrated alcohol USP in 0.9% sodium chloride injection USP. The pH of the solution is between 5.5 and 7.5.

Physical Characteristics

Amyvid is radiolabeled with [18F] fluorine (F 18) that decays by positron (β+) emission to O 18 and has a half-life of 109.77 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 3).

Table 3: Principal Radiation Produced from Decay of Fluorine 18

Radiation Energy Level (keV) Abundance (%)
Positron 249.8 96.9
Gamma 511 193.5

 

Share

Lycopene and fish oil prevent colon cancer

 Uncategorized  Comments Off on Lycopene and fish oil prevent colon cancer
Jul 062013
 

thumbnail image: It Takes Two to a Healthy Colon

Lycopene and fish oil are two substances known for their beneficial properties. The first one, a carotene contained in red fruits such as tomatoes, has been shown to lower the risk of developing digestive track cancers. The second one possesses anti-inflammatory properties thanks to its high content in polyunsaturated fatty acids, such as eicopentaenoic and docosahexaenoic acids

read all at

http://www.chemistryviews.org/details/news/2720971/It_Takes_Two_to_a_Healthy_Colon.html

Share
Jul 052013
 

Fibristal (ulipristal acetate)

Health Canada grants marketing approval for Actavis’ Fibristal to treat uterine fibroids
Health Canada has granted marketing approval for Actavis’ Fibristal (ulipristal acetate) to treat symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery…

 

http://regulatoryaffairs.pharmaceutical-business-review.com/news/health-canada-grants-marketing-approval-for-actavis-fibristal-to-treat-uterine-fibroids-260613

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: